Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
ARA-290 is not FDA-approved and remains investigational in the United States. Classified as a research chemical, it can be purchased legally in most jurisdictions for research use, with the regulatory burden on the purchaser. Personal use exists in a legal gray area with low enforcement risk in the U.S., though stricter regulation applies in some countries. WADA has not formally banned it, but athletes should verify before competitive use.
What Is ARA-290's FDA Status?
ARA-290 (cibinetide) was developed by Araim Pharmaceuticals and has completed Phase I and Phase II clinical trials for diabetic peripheral neuropathy and sarcoidosis-related neuropathy. As of 2026, it remains investigational—not approved for treatment by the FDA or any regulatory authority. It is not available through prescription in any country and cannot be legally marketed for therapeutic use.
The FDA distinguishes between investigational drugs (in active clinical trials) and unapproved drugs (not in trials). ARA-290 technically falls into the investigational category; specific ongoing trials determine its current regulatory pathway. No timeline for FDA approval has been announced publicly.
Understanding the Investigational Drug Framework
In the United States, investigational drugs can be accessed through expanded access programs (compassionate use) if specific criteria are met: no approved alternatives, serious/life-threatening condition, likely benefit. However, ARA-290 expanded access has not been widely publicized, and formal pathways remain limited to clinical trial enrollment.
The DEA does not schedule ARA-290 (it is not a controlled substance). Possession is not a federal crime. However, marketing or selling it as a therapeutic agent is illegal; vendors must label it "for research use only" to remain compliant.
ARA-290 as a Research Chemical
ARA-290 is sold openly by multiple suppliers as a "research chemical" or "research peptide," typically with disclaimers stating "not for human consumption." This labeling allows vendors to operate legally under FDA guidelines; the regulatory burden shifts to the purchaser to ensure compliance with local laws.
Many U.S. states do not have explicit prohibitions against possession of research peptides for personal use. Federal law does not prohibit personal possession of non-scheduled research chemicals. Enforcement is virtually non-existent at the federal level for individuals purchasing research peptides.
The gray area arises from the lack of explicit legalization. State laws vary; some explicitly prohibit "designer drugs" (though peptides are not typically classified as such), while others are silent on the topic.
International Legal Status by Region
Canada: Regulatory status unclear. Likely falls under the Therapeutic Products Directorate (TPD) investigational drug framework. Possession for personal use is probably legal; commercial sales require approval. Enforcement is minimal.
United Kingdom: Available through registered research chemical suppliers. Legal status is gray but permissive; many peptides are sold openly to researchers. Possession for personal use is unlikely to trigger enforcement.
Australia: Stricter than North America/UK. Likely requires Therapeutic Goods Administration (TGA) approval. Possession may be illegal without prescription. Research chemical suppliers exist but operate in a more precarious legal environment.
European Union: Varies by country. Germany and Netherlands have relatively permissive research chemical frameworks. France, Italy, and Spain are stricter. Generally, possession for personal use is unlikely to trigger criminal prosecution, but commercial sales require pharmaceutical licensing.
New Zealand: Follows similar framework to Australia; stricter than UK/Canada.
Sports Regulatory Status and WADA
The World Anti-Doping Agency (WADA) has not formally added ARA-290 to its prohibited list as of 2026. However, its mechanism—tissue protection, anti-inflammatory signaling, potential performance enhancement—could theoretically trigger future scrutiny.
Athletes competing in WADA-tested sports (Olympic sports, professional cycling, etc.) should verify with their anti-doping authority before using ARA-290. The peptide could be interpreted as an indirect performance-enhancing substance, even if not explicitly prohibited.
Legal Penalties and Enforcement Risk
United States: Federal enforcement risk is minimal for individuals. Vendors operating without proper disclaimers ("for research use only") face more significant legal exposure. State-level enforcement varies; in most jurisdictions, personal possession carries minimal to no risk. However, medical practitioners recommending ARA-290 for therapeutic purposes could face regulatory action.
International: Enforcement varies dramatically. Australia has stricter enforcement than Canada. UK enforcement is lax. Always verify local laws before purchasing.
Understanding Different Regulatory Pathways
The FDA has multiple pathways for approving new drugs: standard review (10 months typical), accelerated approval (6 months for serious conditions with unmet needs), priority review (6 months), breakthrough therapy designation (fastest track for conditions lacking alternatives), and fast track. ARA-290 for diabetic neuropathy could qualify for priority or fast track given the large patient population and limited effective treatments.
If approved, ARA-290 would likely be available only through prescription at licensed pharmacies. Insurance coverage would depend on clinical evidence and cost-effectiveness data. Out-of-pocket costs could be $1,000-5,000+ per treatment cycle, depending on pricing set by Astellas.
Post-approval, research chemical ARA-290 would likely become illegal for general sale (only official pharmaceutical product permitted). This mirrors the experience with BPC-157 and TB-500 precursors—once a close analog is FDA-approved, research chemical versions face increased regulatory pressure.
Projected Future Legal Status (2026-2030)
Realistic scenarios:
- FDA approval 2027-2029: ARA-290 becomes prescription-only. Research chemical market shrinks. Cost increases substantially. Patients gain legal access through licensed channels.
- FDA approval delayed to 2030+: Research chemical market continues; gray area persists. Regulatory pressure may increase as clinical evidence accumulates and demand rises.
- FDA approval denied or indefinitely delayed: ARA-290 remains investigational indefinitely. Research chemical category persists; legal status remains ambiguous.
Regardless of FDA outcome, international regulatory paths may proceed independently. Astellas may pursue approval in Europe, Canada, or Australia before/after the U.S.
State-by-State Variations in U.S. Legal Status
Federal law does not explicitly prohibit research peptides, but state laws vary dramatically. Some states have "designer drug" or "analog drug" laws that could theoretically apply to research peptides, though enforcement is virtually non-existent for individual possession:
- California: Broad "designer drug" statute but rarely enforced for peptides. Possession likely legal.
- Florida: Strong "designer drug" laws but peptides not typically targeted. Low risk.
- Texas: Less restrictive; research chemical possession generally tolerated.
- New York: More restrictive but enforcement minimal for peptides. Low to moderate risk.
Bottom line: Check your specific state laws before purchasing. In most U.S. states, personal possession of research peptides carries minimal legal risk. However, some states are more aggressive; if you live in a state with known strict enforcement (California, New York, Florida), exercise greater caution.
How to Stay Legally Compliant
- Verify local laws: Before purchasing, research your jurisdiction's specific regulations. Consult a lawyer if unsure.
- Purchase from legitimate vendors: Use suppliers with proper licensing, documentation, and clear "for research use only" labeling
- Request research-use labeling: Ensure the product arrives labeled "for research use only" and "not for human consumption"
- Document your use: Keep records of purchases (vial numbers, dates, supplier) for your records. Note: this is for your internal tracking, not to establish legal defense.
- Do not resell: Selling ARA-290 increases legal exposure substantially. Possessing for personal use is one thing; distributing is another.
- Avoid medical claims: Do not publicly claim to use ARA-290 for treatment of disease. Privately use is acceptable; public promotion invites regulatory scrutiny.
- Monitor regulatory changes: Follow news on pharmaceutical regulation and ARA-290's approval status. If FDA approval occurs, transition to legal prescription-based access.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →